Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Very Positive)

Rhea-AI Summary

Akebia Therapeutics (NASDAQ: AKBA), a biopharmaceutical company focused on kidney disease treatments, has granted stock options to eight newly-hired employees. The inducement grants total 148,000 shares of common stock with an exercise price of $2.41 per share, matching the closing price on April 30, 2025. The options feature a 4-year vesting schedule with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter. Each option has a 10-year term and is contingent on continued employment with Akebia.

News Market Reaction

+2.51%

1 alert

+2.51% News Effect

On the day this news was published, AKBA gained 2.51%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

05/01/2025 - 04:15 PM

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ^®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase an aggregate of 148,000 shares of Akebia’s common stock on April 30, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $2.41 per share, which is equal to the closing price of Akebia’s common stock on the grant date. The stock options vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with Akebia. Each stock option has a 10-year term and is subject to the terms and conditions of Akebia’s inducement award program and a stock option agreement covering the grant.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact

Mercedes Carrasco
mcarrasco@akebia.com

FAQ

What stock options did Akebia Therapeutics (AKBA) grant to new employees in April 2025?

Akebia granted options to purchase 148,000 shares of common stock at $2.41 per share to eight new employees, with a 4-year vesting schedule and 10-year term.

What is the vesting schedule for AKBA's April 2025 employee stock options?

The options vest over 4 years, with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter, subject to continued employment.